In the News
Hypertension treatment reduced long-term mortality, but intensive glucose control didn't
Hypertension treatment with perindopril-indapamide for 4.5 years had a long-lasting impact on mortality in patients with type 2 diabetes, but intensive glucose control was not associated with any significant benefit, a study found.
Metformin may be associated with low levels of thyroid-stimulating hormone, study finds
Metformin monotherapy may be linked to lower levels of thyroid-stimulating hormone compared with sulfonylurea monotherapy in patients with type 2 diabetes, according to a new study.
Phentermine/topiramate combo helps type 2 diabetes patients lose weight, control glucose
Obese and overweight patients with type 2 diabetes lost more weight and had better glycemic control when treated with phentermine/topiramate extended-release medication than with placebo, 2 industry-funded studies reported.
MKSAP quiz: Severe foot pain in type 1 diabetic
This month's quiz asks readers to evaluate a 42-year-old man with poorly controlled type 1 diabetes who has a 6-day history of severe burning and stabbing pain in both feet that is worse in the toes.
In newly diagnosed type 2 diabetes mellitus, a Mediterranean diet (vs. a low-fat diet) delayed start of glucose-lowering drugs
Patients who were randomized to a low-carbohydrate Mediterranean diet shortly after type 2 diabetes diagnosis delayed their need for medication compared to those put on a low-fat diet in an Italian trial.
GLP-1 agonist plus basal insulin beat other diabetes treatment regimens in meta-analysis
Patients on combination treatment with a glucagon-like peptide-1 receptor (GLP-1) agonist and basal insulin had better HbA1c values, less weight gain, and similar hypoglycemia rates compared to patients on other type 2 diabetes treatment regimens, a recent analysis of previous trials found.
USPSTF recommends screening asymptomatic adults for diabetes
The United States Preventive Services Task Force (USPSTF) is expanding the population it recommends screening for type 2 diabetes, according to a draft recommendation released this week.
New GLP-1 agonist approved
A new glucagon-like peptide-1 (GLP-1) receptor agonist, dulaglutide (Trulicity), was approved to treat type 2 diabetes, along with diet and exercise, the FDA recently announced.
Spotlight on ethnic differences in diabetes
Two recent studies highlighted some differences among ethnic groups in risk and incidence of diabetes.